By Ann Danaiya Usher
The Lancet, May 18, 2019
The Executive Director of the Serum Institute Suresh Jadhav says that he expects the approval process to be completed before the end of the year.
Gavi has already included the new product in its line-up for next year, with a list price of $6 per immunised child. A Gavi spokesperson explained that a country wishing to introduce the new vaccine or to switch to the Serum Institute of India's product must first express demand for the vaccine. UNICEF then initiates procurement activities with the manufacturer. This process can start right away, although supply arrangements can only be finalised when the WHO prequalification is complete.”